The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.

IF 3 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2026-06-29 DOI:10.1080/14737140.2026.2695215

Manabu Natsumeda, Masayasu Okada, Satoshi Nakata, Haruhiko Takahashi, Chinatsu Kakinuma, Calixto-Hope G Lucas, Jun Watanabe, Yoshihiro Tsukamoto, Charles G Eberhart, Akiyoshi Kakita, Junko Murai, Makoto Oishi

{"title":"The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.","authors":"Manabu Natsumeda, Masayasu Okada, Satoshi Nakata, Haruhiko Takahashi, Chinatsu Kakinuma, Calixto-Hope G Lucas, Jun Watanabe, Yoshihiro Tsukamoto, Charles G Eberhart, Akiyoshi Kakita, Junko Murai, Makoto Oishi","doi":"10.1080/14737140.2026.2695215","DOIUrl":null,"url":null,"abstract":"Introduction: Schlafen11 (SLFN11) has emerged as a powerful biomarker of sensitivity to DNA-damaging agents in various cancers. However, not much is known about its role in brain tumors. Conflicting reports show that it is a biomarker for response to cisplatin and a prognostic factor in some brain tumors, such as medulloblastomas, but can even be a negative prognostic factor in others, like glioblastomas.Areas covered: In this review, we discuss what is known about the various roles of SLFN11 in cancer, with special attention to brain tumors. Specifically, we focus on the seemingly dual role of SLFN11 in brain tumors; positive prognostic in some and negative in others. Additionally, we describe some glioma cases with high SLFN11 expression, often showing aggressive presentation, a good response to initial treatment, and subsequent widespread relapse.Expert opinion: In brain tumors such as medulloblastomas and primary central nervous system lymphomas (PCNSL), when total cell killing can be expected by chemotherapy and/or chemoradiotherapy, high SLFN11 expression is a positive prognostic marker. However, SLFN11 can also be highly expressed in mesenchymal tumors, and in cases where total cell killing cannot be achieved, widespread relapse can accompany an initial response.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":3.0000,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2026.2695215","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Schlafen11 (SLFN11) has emerged as a powerful biomarker of sensitivity to DNA-damaging agents in various cancers. However, not much is known about its role in brain tumors. Conflicting reports show that it is a biomarker for response to cisplatin and a prognostic factor in some brain tumors, such as medulloblastomas, but can even be a negative prognostic factor in others, like glioblastomas.

Areas covered: In this review, we discuss what is known about the various roles of SLFN11 in cancer, with special attention to brain tumors. Specifically, we focus on the seemingly dual role of SLFN11 in brain tumors; positive prognostic in some and negative in others. Additionally, we describe some glioma cases with high SLFN11 expression, often showing aggressive presentation, a good response to initial treatment, and subsequent widespread relapse.

Expert opinion: In brain tumors such as medulloblastomas and primary central nervous system lymphomas (PCNSL), when total cell killing can be expected by chemotherapy and/or chemoradiotherapy, high SLFN11 expression is a positive prognostic marker. However, SLFN11 can also be highly expressed in mesenchymal tumors, and in cases where total cell killing cannot be achieved, widespread relapse can accompany an initial response.

查看原文本刊更多论文

Schlafen11在脑肿瘤中的双重作用：化身和化身。

Schlafen11 （SLFN11）已成为多种癌症中对dna损伤剂敏感的强有力的生物标志物。然而，人们对它在脑肿瘤中的作用知之甚少。相互矛盾的报告显示，它是顺铂反应的生物标志物，也是一些脑肿瘤（如髓母细胞瘤）的预后因素，但在其他脑肿瘤（如胶质母细胞瘤）中甚至可能是一个阴性预后因素。涵盖领域：在这篇综述中，我们讨论了SLFN11在癌症中的各种已知作用，特别关注脑肿瘤。具体来说，我们关注SLFN11在脑肿瘤中的双重作用；一些人预后良好，另一些人预后不良。此外，我们描述了一些SLFN11高表达的胶质瘤病例，通常表现为侵袭性表现，对初始治疗反应良好，随后广泛复发。专家意见：在髓母细胞瘤和原发性中枢神经系统淋巴瘤（PCNSL）等脑肿瘤中，当化疗和/或放化疗可预期杀死全部细胞时，高SLFN11表达是一个积极的预后标志。然而，SLFN11也可以在间充质肿瘤中高表达，在不能完全杀死细胞的情况下，广泛的复发可能伴随着初始反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.